COVID-19 therapies update: There are three potential pathways forming a bridge to a vaccine
Listen now
Description
You’ve probably heard the anti-malarial drug hydroxychloroqine is getting a hard look as a potential therapeutic agent in the fight against COVID-19. However, as Harvard Health Publishing senior faculty editor Dr. Rob Shmerling points out, evidence remains weak. On the brighter side, he points to three potential avenues in COVID-19 research where therapies may be put to use while a vaccine remains in development.
More Episodes
With the COVID-19 pandemic still ongoing, and the annual flu season fast approaching, what can people expect when these two illnesses collide? Are we at greater risk for getting either virus? And could this encounter change how we approach health care now and in the future? Matthew Solan,...
Published 10/09/20
Recent record temperatures in the U.S. suggest that heat-related illness isn’t confined to the dog days of summer. Dr. Aaron Bernstein, the interim director of the Center for Climate Health and the Global Environment at the Harvard T.H. Chan School of Public Health, describes the symptoms to...
Published 09/28/20
Right up there on the list of unpleasant medical topics best avoided includes problems that can befall the male genitourinary system. Despite its prosaic purpose, the machinery associated with eliminating waste and fostering procreation possesses a certain artfulness. Usually it can be safely...
Published 09/08/20
Links
Twitter
Facebook
Instagram
Patreon
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
See hourly chart positions and more than 30 days of history.
Get Chartable Analytics »
See hourly chart positions and more than 30 days of history.
